Indi Molecular® has developed synthetic small molecule targeted oncology therapeutics against overexpressed folate receptors in ovarian cancer and KRAS G12D expressing pancreatic cancers.  We created these therapeutic molecules using a breakthrough, synthetic protein chemistry platform: Protein Catalyzed Capture (PCC) agents. These targeted therapeutics are small synthetic peptide replacements for antibody-based therapeutics. 

SPECIFICITY

Specific to the chosen epitope of the desired target protein

Affinity

Pico-molar and low nano-molar binding affinities with demonstrable cooperative binding for affinity enhancement

SOLUBLE

D-amino acids yield stable molecules, retain good water solubility and are renally cleared

Tunable

Fully synthetic small peptides for rapid synthesis and robust manufacturing

SPEED

Go from an identified epitope to nanomolar binding affinity in 4 weeks

IN VIVO

PCC have demonstrated in vivo functional activity and can deliver a therapeutic effect against both intra and extracellular targets